Insulet Corporation (PODD) financials
Insulet revenue and earnings by year
Insulet's revenue was $2.71 billion in the fiscal year to December 31, 2025, up 30.7% from the year before. Net income was $247 million, 9.1% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 24.9% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.71 | 2.07 | 1.70 | 1.31 | 1.10 | 0.90 | 0.74 | 0.56 | 0.46 | 0.37 |
| Revenue growth | 30.7% | 22.1% | 30.0% | 18.8% | 21.5% | 22.5% | 30.9% | 21.6% | 26.4% | — |
| Gross profit | 1.94 | 1.45 | 1.16 | 0.81 | 0.75 | 0.58 | 0.48 | 0.37 | 0.28 | 0.21 |
| Gross margin | 71.6% | 69.8% | 68.3% | 61.7% | 68.4% | 64.4% | 65.1% | 65.7% | 59.8% | 57.5% |
| Operating income | 0.47 | 0.31 | 0.22 | 0.04 | 0.13 | 0.05 | 0.05 | 0.03 | -0.01 | -0.01 |
| Operating margin | 17.5% | 14.9% | 13.0% | 2.9% | 11.5% | 5.7% | 6.8% | 4.9% | -1.6% | -2.9% |
| Net income | 0.25 | 0.42 | 0.21 | 0.00 | 0.02 | 0.01 | 0.01 | 0.00 | -0.03 | -0.03 |
| Net margin | 9.1% | 20.2% | 12.2% | 0.4% | 1.5% | 0.8% | 1.6% | 0.6% | -5.8% | -7.9% |
| Diluted EPS | $3.48 | $5.78 | $2.94 | $0.07 | $0.24 | $0.10 | $0.18 | $0.05 | — | — |
| Free cash flow | 0.35 | 0.30 | 0.04 | -0.04 | -0.19 | -0.08 | -0.07 | -0.12 | -0.03 | -0.01 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open PODD in Markets.
How Insulet makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| U S Omnipod | $544M | 67.9% |
| International Omnipod | $252M | 31.4% |
| Drug Delivery | $5.80M | 0.7% |
See also: PODD valuation and P/E history · PODD returns
No forecast, no recommendation. This page describes Insulet Corporation from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.